Singer Michael A, Cohen Steven R, Groth Sylvia L, Porbandarwalla Salman
Medical Center Ophthalmology Associates (MCOA), San Antonio, Texas, USA.
Clin Ophthalmol. 2013;7:1377-83. doi: 10.2147/OPTH.S46235. Epub 2013 Jul 8.
To examine short-term effects of ranibizumab versus bevacizumab on reduction of optical coherence tomography (OCT) central macular thickness (CMT) in patients with macular edema secondary to retinal vein occlusions (RVOs).
This is a retrospective analysis in which patients with RVOs were injected with either bevacizumab or ranibizumab. At 2 weeks, all patients were injected with a dexamethasone intravitreal implant (Ozurdex®). CMT on OCT and best-corrected visual acuity were obtained at baseline, at 2 weeks (just prior to the dexamethasone intravitreal implant), and 6 weeks.
Sixty-four patients received injections (32 bevacizumab; 32 ranibizumab). At 2 weeks, bevacizumab group had a mean (±standard error of mean [SEM]) CMT reduction of 26.2% ± 3.4% versus 47% ± 3.5% reduction with ranibizumab (P < 0.0001). At 6 weeks, there was a 31.6% ± 3.2% CMT reduction with bevacizumab versus 52% ± 3.2% with ranibizumab (P < 0.0001). At 2 weeks, 15 (9%) of bevacizumab patients versus 25 (78.1%) ranibizumab patients achieved OCT CMT < 300 μm (P = 0.0192). At 6 weeks, 18 (56.3%) of bevacizumab compared to 30 (93.8%) of ranibizumab patients achieved CMT < 300 μm (P = 0.0010). Visual acuity was not significantly different at each time interval between the groups.
Ranibizumab appears to have a greater effect in the short-term of decreasing macular edema on OCT when compared to bevacizumab in patients with RVOs.
研究雷珠单抗与贝伐单抗对视网膜静脉阻塞（RVO）继发黄斑水肿患者光学相干断层扫描（OCT）中心黄斑厚度（CMT）降低的短期影响。
这是一项回顾性分析，RVO患者接受了贝伐单抗或雷珠单抗注射。在2周时，所有患者均接受了地塞米松玻璃体内植入物（Ozurdex®）注射。在基线、2周（即将注射地塞米松玻璃体内植入物之前）和6周时获取OCT上的CMT和最佳矫正视力。
64例患者接受了注射（32例接受贝伐单抗；32例接受雷珠单抗）。在2周时，贝伐单抗组CMT平均降低（±平均标准误差[SEM]）26.2%±3.4%，而雷珠单抗组降低47%±3.5%（P<0.0001）。在6周时，贝伐单抗组CMT降低31.6%±3.2%，雷珠单抗组降低52%±3.2%（P<0.0001）。在2周时，15例（9%）接受贝伐单抗治疗的患者与25例（78.1%）接受雷珠单抗治疗的患者OCT CMT<300μm（P=0.0192）。在6周时，18例（56.3%）接受贝伐单抗治疗的患者与30例（93.8%）接受雷珠单抗治疗的患者CMT<300μm（P=0.0010）。两组在各时间间隔的视力无显著差异。
与贝伐单抗相比，雷珠单抗在短期内对RVO患者OCT上黄斑水肿的减轻似乎有更大效果。
